We are monitoring the impact of COVID-19 on Europe Next Generation Antibody Therapeutics Market Get in touch with us for detailed analysis Know More
Pulished Date February, 2020
ID: 5227
Share on
Share on

Europe Next Generation Antibody Therapeutics Market Research Report - Segmented By Therapeutics, Technology & Country (UK, France, Spain, Germany, Italy, Russia, Sweden, Denmark, Switzerland, Netherlands, Turkey, Czech Republic & Rest of Europe) - Industry Analysis on Size, Share, Trends, Growth, Forecast | 2019 - 2024

Pulished: February, 2020
ID: 5227
Pages: 145

Europe Next-Generation Antibody Therapeutics Market Size & Growth (2019 – 2024):

As Per the Report, the Europe Next-Generation Antibody Therapeutics Market size is valued at USD 0.96 billion in 2019 and is expected to grow at a CAGR of 14.2% to reach USD 1.86 billion by 2024 during the forecast period 2019-2024. It captures 25% of the global market.

Next-generation antibody therapeutics have high efficiency and are safer. Rapid advancements in monoclonal antibodies technology are the reason for this. These advances have improved bifunctional properties, decreased functional size along with immunogenicity. Several medical conditions like cancer; autoimmune diseases, etc. are treated using these technologies because of its enhanced properties.

A rising number of cases of chronic diseases, rapid advancements in technology, higher investment in R&D and increasing healthcare expenditure are the primary drivers of market growth. On the other hand, strict administrative guidelines and regulatory requirements and inordinate delays in approval for new drugs along with their high costs are the primary restraints of market growth.

Europe Next-Generation Antibody Therapeutics Market has been segmented and sub-segmented into the following categories

  • By Therapeutics: Oncology and Autoimmune/Inflammatory Diseases
  • By Technology: Antibody-Drug Conjugates (ADCs), Bispecific Antibodies (BsAbs), Fc Engineered Antibodies, Antibody Fragments and Antibody-like Proteins, and Biosimilar Antibody Products.
  • By Country: UK, France, Spain, Germany, Italy, Russia, Sweden, Denmark, Switzerland, Netherlands, Turkey, Czech Republic & Rest of Europe.

On the basis of region, Europe is the second-largest market and is expected to remain so through bridging the deficit with North America towards the tail end of the forecast period.

Promising Companies dominating the Europe Next-Generation Antibody Therapeutics Market include Roche, Seattle Genetics, Takeda, Dyax Corp., and Immunogen, Amgen, Inc., Biogen, Kyowa Hakko Kirin Co., Ltd., AstraZeneca, Pfizer, Inc., and Xencor, Inc.

1. Introduction        

                1.1 Market Definition                    

                1.2 Study Deliverables                  

                1.3 Base Currency, Base Year and Forecast Periods 

                1.4 General Study Assumptions                

2. Research Methodology                  

                2.1 Introduction      

                2.2 Research Phases                      

       2.2.1 Secondary Research           

       2.2.2 Primary Research 

       2.2.3 Econometric Modelling      

       2.2.4 Expert Validation  

                2.3 Analysis Design

                2.4 Study Timeline 

3. Overview              

                3.1 Executive Summary                

                3.2 Key Inferences

                3.3 Epidemiology     

4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)           

                4.1 Market Drivers 

                4.2 Market Restraints                    

                4.3 Key Challenges

                4.4 Current Opportunities in the Market     

5. Market Segmentation                     

                5.1 Technology                 

       5.1.1 Introduction           

       5.1.2 Antibody-Drug Conjugates (ADCs)               

       5.1.3 Bispecific Antibodies (BsAbs)          

       5.1.4 Fc Engineered Antibodies 

       5.1.5 Antibody Fragments and Antibody-like Proteins    

       5.1.6 Biosimilar Antibody Products          

       5.1.7 Y-o-Y Growth Analysis, By Technology        

       5.1.8 Market Attractiveness Analysis, By Technology      

       5.1.9 Market Share Analysis, By Technology        

                5.2 Therapeutic Application                        

       5.2.1 Introduction           

       5.2.2 Oncology 

       5.2.3 Autoimmune/Inflammatory Diseases         

       5.2.4 Y-o-Y Growth Analysis, By Therapeutic Application               

       5.2.5 Market Attractiveness Analysis, By Therapeutic Application             

       5.2.6 Market Share Analysis, By Therapeutic Application               

6. Geographical Analysis                     

                6.1 Introduction      

       6.1.1 Regional Trends    

       6.1.2 Impact Analysis     

       6.1.3 Y-o-Y Growth Analysis        

                       6.1.3.1 By Geographical Area

                       6.1.3.2 By Technology

                       6.1.3.3 By Therapeutic Application

       6.1.4  Market Attractiveness Analysis     

                       6.1.4.1 By Geographical Area

                       6.1.4.2 By Technology

                       6.1.4.3 By Therapeutic Application

       6.1.5  Market Share Analysis      

                       6.1.5.1 By Geographical Area

                       6.1.5.2 By Technology

                       6.1.5.3 By Therapeutic Application

                6.2 U.K                 

                6.3 Spain    

                6.4 Germany                     

                6.5 Italy      

                6.6 France 

               6.7 Rest of Europe

7. Strategic Analysis              

                7.1 PESTLE analysis

       7.1.1 Political     

       7.1.2 Economic 

       7.1.3 Social         

       7.1.4 Technological         

       7.1.5 Legal          

       7.1.6 Environmental       

                7.2 Porter’s Five analysis     

       7.2.1 Bargaining Power of Suppliers        

       7.2.2 Bargaining Power of Consumers    

       7.2.3 Threat of New Entrants     

       7.2.4 Threat of Substitute Products and Services              

       7.2.5 Competitive Rivalry within the Industry     

8. Market Leaders' Analysis               

                8.1 Roche  

       8.1.1 Overview 

       8.1.2 Product Analysis   

       8.1.3 Financial analysis  

       8.1.4 Recent Developments       

       8.1.5 SWOT analysis       

       8.1.6 Analyst View          

                8.2 Seattle Genetics                       

                8.3 Takeda

                8.4 Dyax Corp.                  

                8.5 Immunogen      

                8.6 Amgen, Inc.       

                8.7 Biogen 

                8.8 Kyowa Hakko Kirin Co., Ltd.                 

                8.9 AstraZeneca      

                8.10 Pfizer, Inc.                

9. Competitive Landscape                  

                9.1 Market share analysis   

                9.2 Merger and Acquisition Analysis                       

                9.3 Agreements, Collaborations, and Joint Ventures

                9.4 New Product Launches

10. Market Outlook and Investment Opportunities                

Appendix                  

                a) List of Tables                

                b) List of Figures     

  • Regional and country-level analysis and forecasts of the study market; providing Insights on the major countries/regions in which this industry is blooming and to also identify the regions that are still untapped
  • The segment-level analysis in terms of product type By Technology market size forecasts and estimations to detect key areas of industry growth in detail
  • Identification of key drivers, restraints, opportunities and challenges (DROC) in the market and their impact on shifting market dynamics
  • Study of the effect of exogenous and endogenous factors that affect the global market; which includes broadly demographic, economics, and political, among other macro-environmental factors presented in an extensive PESTLE Analysis
  • Study the micro environment factors that determine the overall profitability of an Industry, using Porter’s five forces analysis for analyzing the level of competition and business strategy development
  • A comprehensive list of key market players along with their product portfolio, current strategic interests, key financial information, legal issues, SWOT analysis and analyst overview to study and sustain the market environment
  • Competitive landscape analysis listing out the mergers, acquisitions, collaborations in the field along with new product launches, comparative financial studies and recent developments in the market by the major companies
  • An executive summary, abridging the entire report in such a way that decision-making personnel can rapidly become acquainted with background information, concise analysis and main conclusions
  • Expertly devised analyst overview along with Investment opportunities to provide both individuals and organizations a strong financial foothold in the market
  1. Europe Next Generation Antibody Therapeutics Market By Technology, From 2019-2024 ( USD Billion )
  2. Europe Antibody-Drug Conjugates (ADCs) Market By Region, From 2019-2024 ( USD Billion )
  3. Europe Bispecific Antibodies (BsAbs) Market By Region, From 2019-2024 ( USD Billion )
  4. Europe Fc Engineered Antibodies Market By Region, From 2019-2024 ( USD Billion )
  5. Europe Antibody Fragments and Antibody-like Proteins Market By Region, From 2019-2024 ( USD Billion )
  6. Europe Biosimilar Antibody Products Market By Region, From 2019-2024 ( USD Billion )
  7. Europe Next Generation Antibody Therapeutics Market By Therapeutic Application, From 2019-2024 ( USD Billion )
  8. Europe Oncology Market By Region, From 2019-2024 ( USD Billion )
  9. Europe Autoimmune/Inflammatory Diseases Market By Region, From 2019-2024 ( USD Billion )
  10. U.K. Next Generation Antibody Therapeutics Market By Technology, From 2019-2024 ( USD Billion )
  11. U.K. Next Generation Antibody Therapeutics Market By Therapeutic Application, From 2019-2024 ( USD Billion )
  12. Germany Next Generation Antibody Therapeutics Market By Technology, From 2019-2024 ( USD Billion )
  13. Germany Next Generation Antibody Therapeutics Market By Therapeutic Application, From 2019-2024 ( USD Billion )
  14. France Next Generation Antibody Therapeutics Market By Technology, From 2019-2024 ( USD Billion )
  15. France Next Generation Antibody Therapeutics Market By Therapeutic Application, From 2019-2024 ( USD Billion )
  16. Italy Next Generation Antibody Therapeutics Market By Technology, From 2019-2024 ( USD Billion )
  17. Italy Next Generation Antibody Therapeutics Market By Therapeutic Application, From 2019-2024 ( USD Billion )
  18. Spain Next Generation Antibody Therapeutics Market By Technology, From 2019-2024 ( USD Billion )
  19. Spain Next Generation Antibody Therapeutics Market By Therapeutic Application, From 2019-2024 ( USD Billion )

Please wait. . . . Your request is being processed

Related Reports

LICENCE TYPE

$ 1234 3335

Clients
clients
clients
clients
clients
clients
clients
Click for Request Sample